Fetal Transplant: From 2 Different Sources
A procedure in which cells – for example, from the pancreas – are taken from an aborted FETUS and then transplanted into the malfunctioning organ (pancreas) of an individual with a disorder of that organ (in this case, diabetes). The cells from the fetus are intended to take over the function of the host’s diseased or damaged cells. Fetal brain cells have also been transplanted into brains of people suffering from PARKINSONISM. These treatments are at an experimental stage.
a research method in which specific cells are taken from a normal fetus, with the informed consent of the mother following her request for termination of pregnancy, for transplantation into a person suffering from a specific disease. These fetal cells would take over the function of the specific diseased or damaged cells of the host. Examples are fetal brain cells transplanted into the affected part of the brain in a patient suffering from Parkinson’s disease, and fetal pancreatic cells transplanted into the pancreas of a juvenile diabetic. Other diseases are being investigated experimentally with a view to using fetal transplants. Such procedures involve major ethical considerations.
A procedure performed during a mother’s labour in which a blood sample is taken from a vein in the scalp of the FETUS. This enables tests to be performed that indicate whether the fetus is, for example, suffering from a shortage of oxygen (HYPOXIA). If so, the obstetrician will usually accelerate the baby’s birth.... fetal blood sampling
Transplantation of tissues or organs of the body are de?ned as an allotransplant, if from another person; an autotransplant, if from the patient him or herself – for example, a skin graft (see GRAFT; SKIN-GRAFTING); and a xenotransplant, if from an animal.
The pioneering success was achieved with transplantation of the kidney in the 1970s; this has been most successful when the transplanted kidney has come from an identical twin. Less successful have been live transplants from other blood relatives, while least successful have been transplants from other live donors and cadaver donors. The results, however, are steadily improving. Thus the one-year functional survival of kidneys transplanted from unrelated dead donors has risen from around 50 per cent to over 80 per cent, and survival rates of 80 per cent after three years are not uncommon. For a well-matched transplant from a live related donor, the survival rate after ?ve years is around 90 per cent. And, of course, if a transplanted kidney fails to function, the patient can always be switched on to some form of DIALYSIS. In the United Kingdom the supply of cadaveric (dead) kidneys for transplantation is only about half that necessary to meet the demand.
Other organs that have been transplanted with increasing success are the heart, the lungs, the liver, bone marrow, and the cornea of the eye. Heart, lung, liver and pancreas transplantations are now carried out in specialist centres. It is estimated that in the United Kingdom, approximately 200 patients a year between the ages of 15 and 55 would bene?t from a liver transplant if an adequate number of donors were available. More than 100 liver transplants are carried out annually in the United Kingdom and one-year-survival rates of up to 80 per cent have been achieved.
The major outstanding problem is how to prevent the recipient’s body from rejecting and destroying the transplanted organ. Such rejection is part of the normal protective mechanism of the body (see IMMUNITY). Good progress has been made in techniques of tissue-typing and immunosuppression to overcome the problem. Drugs are now available that can suppress the immune reactions of the recipient, which are responsible for the rejection of the transplanted organ. Notable among these are CICLOSPORIN A, which revolutionised the success rate, and TACROLIMUS, a macrolide immunosuppressant.
Another promising development is antilymphocytic serum (ALS), which reduces the activity of the lymphocytes (see LYMPHOCYTE) cells which play an important part in maintaining the integrity of the body against foreign bodies.
Donor cards are now available in all general practitioners’ surgeries and pharmacies but, of the millions of cards distributed since 1972, too few have been used. The reasons are complex but include the reluctance of the public and doctors to consider organ donation; poor organisation for recovery of donor kidneys; and worries about the diagnosis of death. A code of practice for procedures relating to the removal of organs for transplantation was produced in 1978, and this code has been revised in the light of further views expressed by the Conference of Medical Royal Colleges and Faculties of the United Kingdom on the Diagnosis of Brain Death. Under the Human Tissue Act 1961, only the person lawfully in possession of the body or his or her designate can authorise the removal of organs from a body. This authorisation may be given orally.
Patients who may become suitable donors after death are those who have suffered severe and irreversible brain damage – since such patients will be dependent upon arti?cial ventilation. Patients with malignant disease or systemic infection, and patients with renal disease, including chronic hypertension, are unsuitable.
If a patient carries a signed donor card or has otherwise recorded his or her wishes, there is no legal requirement to establish lack of objection on the part of relatives – although it is good practice to take account of the views of close relatives. If a relative objects, despite the known request by the patient, sta? will need to judge, according to the circumstances of the case, whether it is wise to proceed with organ removal. If a patient who has died is not known to have requested that his or her organs be removed for transplantation after death, the designated person may only authorise the removal if, having made such reasonable enquiry as may be practical, he or she has no reason to believe (a) that the deceased had expressed an objection to his or her body being so dealt with after death, or (b) that the surviving spouse or any surviving relative of the deceased objects to the body being so dealt with. Sta? will need to decide who is best quali?ed to approach the relatives. This should be someone with appropriate experience who is aware how much the relative already knows about the patient’s condition. Relatives should not normally be approached before death has occurred, but sometimes a relative approaches the hospital sta? and suggests some time in advance that the patient’s organs might be used for transplantation after death. The sta? of hospitals and organ exchange organisations must respect the wishes of the donor, the recipient and their families with respect to anonymity.
Relatives who enquire should be told that some post-mortem treatment of the donor’s body will be necessary if the organs are to be removed in good condition. It is ethical (see ETHICS) to maintain arti?cial ventilation and heartbeat until removal of organs has been completed. This is essential in the case of heart and liver transplants, and many doctors think it is desirable when removing kidneys. O?cial criteria have been issued in Britain to recognise when BRAIN-STEM DEATH has occurred. This is an important protection for patients and relatives when someone with a terminal condition
– usually as a result of an accident – is considered as a possible organ donor.... transplantation
The insertion of a piece of bone from another site or from another person to ?ll a defect, provide supporting tissue, or encourage the growth of new bone.... bone transplant
A disorder of newborn infants that is caused by the toxic effects on the growing FETUS of excessive amounts of alcohol taken by the mother. Low birth-weight and retarded growth are the main consequences, but affected babies may have hand and facial deformities and are sometimes mentally retarded.... fetal alcohol syndrome
An operation in which a patient’s diseased lungs and heart are removed and replaced with donor organs from someone who has been certi?ed as ‘brain dead’ (see BRAIN-STEM DEATH). As well as the technical diffculties of such an operation, rejection by the recipient’s tissues of donated heart and lungs has proved hard to overcome. Since the early 1990s, however, immunosuppressant drug therapy (see CICLOSPORIN; TRANSPLANTATION) has facilitated the regular use of this type of surgery. Even so, patients receiving transplanted hearts and lungs face substantial risks such as lung infection and airway obstruction as well as the long-term problems of transplant rejection.... heart-lung transplant
UK legislation that lays down the framework and rules governing organ transplantation. The UK Transplant Support Service Authority (UKTSSA), a special health authority set up in 1991, is responsible for administering the NHS Organ Donor Registry and the Act (see APPENDIX 7: STATUTORY ORGANISATIONS).... human organs transplants act
See TRANSPLANTATION.... organ transplantation
These have almost completely replaced BONE MARROW TRANSPLANT, used to treat malignancies such as LEUKAEMIA and LYMPHOMA for the past 20 years. The high doses of CHEMOTHERAPY or RADIOTHERAPY used to treat these diseases destroy the bone marrow which contains stem cells from which all the blood cells derive. In 1989 stem cells were found in the blood during recovery from chemotherapy. By giving growth factors (cytokines), the number of stem cells in the blood increased for about three to four days. In a peripheral-blood stem-cell transplant, these cells can be separated from the peripheral blood, without a general anaesthetic. The cells taken by either method are then frozen and returned intravenously after the chemotherapy or radiotherapy is completed. Once transplanted, the stem cells usually take less than three weeks to repopulate the blood, compared to a month or more for a bone marrow transplant. This means that there is less risk of infection or bleeding during the recovery from the transplant. The whole procedure has a mortality risk of less than 5 per cent – half the risk of a bone marrow transplant.... peripheral-blood stem-cell transplants
Before the advent of small-bowel transplants, long-term intravenous feeding (total parenteral nutrition or TPN) was the last option for patients with chronic intestinal failure. Most recipients are children, and small-bowel transplantation is currently reserved for patients unable to continue on long-term parenteral nutrition. The main constraints to small-bowel transplantation are the intensity of rejection (necessitating high levels of immunosuppression), and the lack of donors who are the same size as the recipient (a particular problem for children).... small-bowel transplantantion
In the UK, this NHS authority (UKTSSA) provides a 24-hour service for matching, allocating and distributing organs. It is also responsible for keeping the records of all patients awaiting transplants. Established in 1991, the authority allocates donor organs without favour, following protocols set by advisory groups. It also administers the Human Organ Transplant Act on behalf of the Department of Health. (See TRANSPLANTATION.)... transplant support services authority
See corneal graft.... corneal transplant
Another term for kidney transplant.... renal transplant
(FASD, fetal alcohol syndrome, FAS) a condition of newborn babies that results from the toxic effects on the fetus of maternal alcohol abuse. Babies have a low birth weight and growth is retarded. They have a small head (*microcephaly), low-set ears, eye, nose, lip, and nail abnormalities, and disturbances of behaviour and intellect. The greater the alcohol abuse, the more severe the fetal manifestations.... fetal alcohol spectrum disorder
a graph, customized to a pregnant woman’s height, weight, and other factors, that plots *fundal height and estimated fetal weight on ultrasound against weeks of gestation. The graph, which shows centile lines (see centile chart), improves prediction of a baby who is *small for gestational age.... fetal growth chart
see intrauterine growth restriction.... fetal growth restriction
(fetal graft) the introduction of an ovum, fertilized in vitro and developed to the *blastocyst stage, into the uterus of a postmenopausal woman in order that she may become pregnant. Before this procedure, the woman’s uterus must be prepared, by hormone therapy, to receive and nurture the blastocyst. Hormone treatment is continued throughout the pregnancy.... fetal implant
an electrical wire set into a sharp spiral metal tip and encased in a plastic sheath. It is attached to the fetal scalp for direct measurement of fetal heart rate by electrical activity.... fetal scalp electrode
see orthotopic transplantation.... heterotopic transplantation
death of a fetus in the uterus after 24 weeks of gestation. See stillbirth.... intrauterine fetal death
a new technique still under evaluation for curing type 1 *diabetes mellitus, which involves the injection of donated cells from the pancreatic *islets of Langerhans into the liver, where it is hoped they will seed and survive. The transplanted cells then take over insulin production from the recipient’s diseased pancreas.... islet cell transplantation
transplantation of a donor organ or tissue (usually the liver) into a recipient at the site where the recipient’s organ has been removed. In contrast, heterotopic transplantation involves the preservation of the recipient’s organ in its natural site and the addition of the donor organ at another site.... orthotopic transplantation
see transplantation.... renal transplantation